查詢結果分析
相關文獻
- 腹直肌鞘血腫合併慢性阻塞性肺病: 病例報告
- Lung Volume Reduction Surgery--A Case Report
- Ariflo[fef0]--A Brief Report on a New Second-Generation Phosphodiesterase 4 Inhibitor
- Acute Chronic Respiratory Failure Complicated by Undetected Obstructive Sleep Apnea Syndrome
- 護理一位慢性阻塞性肺病個案之經驗
- 慢性阻塞性肺病的復健工作
- A Multidisciplinary Pulmonary Rehabilitation Program for Patients with Moderately Severe Chronic Obstructive Pulmonary Disease
- Agrobacterium Radiobacter Bacteremia in a Patient with Chronic Obstructive Pulmonary Disease
- 硫酸鎂注射在於治療慢性阻塞性肺病併急性發作的功效
- 慢性阻塞性肺病的藥物治療
頁籤選單縮合
題 名 | 新Phosphodiesterase 4抑制劑--Roflumilast=A Novel Phosphodiesterase 4 Inhibitor-- Roflumilast |
---|---|
作 者 | 李建瑩; 施宏哲; | 書刊名 | 藥學雜誌 |
卷 期 | 30:3=120 2014.09[民103.09] |
頁 次 | 頁44-48 |
分類號 | 418.2216 |
關鍵詞 | 慢性阻塞性肺病; Phosphodiesterase 4抑制劑; PDE 4抑制劑; Roflumilast; Chronic obstructive pulmonary disease; Phosphodiesterase 4 inhibitor; |
語 文 | 中文(Chinese) |
中文摘要 | 慢性阻塞性肺病 (chronic obstructive pulmonary disease; COPD) 是慢性疾病及死亡 的主要原因之一。茶鹼類藥品 theophylline,具有擴張支氣管的作用和中樞神經興奮 作用,用於治療氣喘和 COPD,為一非選擇性 phosphodiesterase 抑制劑。最近研發的 phosphodiesterase 4 (PDE 4) 抑制劑藥品 roflumilast,適用於重度 COPD,並伴隨頻繁 惡化病史的成年慢性支氣管炎患者,做為附加於支氣管擴張劑的維持治療,不做為緩 解急性支氣管痙攣的急救用藥。Roflumilast 的活性代謝物 roflumilast N-oxide 可選擇 作用於 PDE4,主要作用為抑制肺臟細胞 cAMP 的分解,增加肺臟細胞內 cAMP 的含 量,降低肺臟細胞內嗜中性白血球 (neutrophil) 和嗜酸性白血球 (eosinophil) 以減輕發 炎反應,並沒有直接的支氣管擴張作用。Roflumilast 每日服用一次500 mcg,可能需 要服用數週才能顯現療效。 |
英文摘要 | Chronic obstructive pulmonary disease (COPD) is one of the leading cause in chronic diseases. Bronchodilator theophylline, a non-selective PDE4 inhibitor, is used in the treatment of asthma and COPD. A novel PDE4 inhibitor roflumilast is indicated for the treatment of severe COPD (FEV1 less than 50% of predicted value post bronchodilator treatment) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as maintained on to bronchodilator treatment. Roflumilast and its active metabolite (roflumilast N-oxide) are selective PDE4 inhibitors, therefore a major cAMP-metabolizing enzyme in lung tissue is inhibited and the neutrolhil and eosinophil cell counts in the lungs are reduced. The recommended dose is 500 micrograms roflumilast once daily and it may need to be taken for several weeks to achieve its effect. |
本系統中英文摘要資訊取自各篇刊載內容。